Skip to main content

Table 1 Clinical effects of high H 2 water and patient characteristics at baseline, and 4, 8, and 12 weeks

From: Consumption of water containing a high concentration of molecular hydrogen reduces oxidative stress and disease activity in patients with rheumatoid arthritis: an open-label pilot study

  Patients Disease duration Urinary 8-OHdG (ng/mg Cr) DAS28 ACPA (U/ml) Medications  
      Baseline 4w 8w 12w Baseline 4w 8w 12w Baseline 4w 8w 12w MTX (mg/w) Duration Abatacept (mg/4w) Duration Response
Patient number Sex Age Y M               Y M   Y M  
1 F 67 3 2 10.1 10.0 7.7 6.0 3.28 2.45 2.40 1.94 300 204 254 226 6 2 0 500 1 2 good
2 F 69 5 0 18.0 16.2 12.0 11.5 2.90 2.95 2.53 2.62 <0.6 <0.6 <0.6 <0.6 4 2 1     non-response
3 F 76 11 0 11.0 8.1 7.8 7.8 4.61 3.71 3.28 3.01 52.4 47.2 58.0 56.6 6 3 0     good
4 F 51 2 1 11.4 11.3 9.1 9.4 3.00 2.79 2.86 2.30 <0.6 <0.6 <0.6 <0.6 6 1 6     moderate
5 F 41 2 0 10.9 9.9 11.3 10.0 4.55 3.43 3.06 3.13 6.9 6.2 9.2 14.5 none good
6 F 42 2 2 15.3 12.6 11.6 10.8 4.63 4.03 2.44 2.57 <0.6 <0.6 <0.6 <0.6 6 1 4     good
7 F 86 5 0 10.0 6.5 7.1 7.1 4.67 3.79 3.78 3.00 0.8 <0.6 <0.6 <0.6 none good
8 F 40 10 0 nd nd 3.9 4.9 2.88 1.25 1.50 0.99 13.5 14.5 15.4 16.8 6 2 2     good
9 F 41 2 1 8.7 7.7 7.3 9.0 5.38 4.35 4.37 4.22 34.3 36.4 57.6 65.7 8 1 6     moderate
10 M 55 2 3 9.3 8.3 9.7 11.5 4.62 3.44 3.28 3.06 532 258 299 223 6 1 8     good
11 F 56 2 0 12.0 8.2 10.8 10.9 5.47 5.22 5.06 4.16 <0.6 <0.6 <0.6 <0.6     500 0 8 good
12 M 40 2 1 5.2 4.9 4.9 6.4 1.95 1.96 1.52 1.59 <0.6 <0.6 <0.6 <0.6 6 1 4     non-response
13 F 64 13 0 nd 8.1 11.2 9.0 2.72 2.14 2.32 2.21 490 299 266 256 4 7 0     non-response
14 F 58 2 0 10.7 8.4 8.5 10.5 3.21 3.03 2.93 3.04 <0.6 <0.6 <0.6 <0.6 6 1 2     non-response
15 F 74 3 0 6.5 6.8 5.7 5.3 2.91 2.52 2.30 1.30 <0.6 <0.6 <0.6 <0.6 none good
16 F 69 0 8 7.6 6.5 8.6 5.4 4.07 2.78 2.54 0.99 2 3.7 <0.6 1.9 none good
17 M 42 0 9 7.9 5.7 6.6 7.2 3.25 2.03 2.27 1.11 <0.6 <0.6 <0.6 <0.6 6   6     good
18 F 49 0 5 10.6 8.5 7.2 9.3 4.91 3.46 2.83 1.17 <0.6 <0.6 <0.6 <0.6 none good
19 F 57 0 10 9.5 9.4 9.2 10.7 3.38 2.87 2.50 1.82 <0.6 <0.6 <0.6 <0.6 none good
20 F 41 0 8 5.2 5.0 4.4 3.8 4.20 2.29 2.91 0.99 <0.6 <0.6 <0.6 <0.6 none good
  1. And, no urine sample; DAS28, disease activity score in 28 joints; ACPA, antibodies against cyclic citrullinated peptides.